🔴 Ironwood Pharmaceuticals is trading 5% down in pre-market — no confirmed catalyst identified

Ironwood Pharmaceuticals is trading at $3.56, down 5.48%, in pre-market; no specific confirmed catalyst has been identified.

• On October 16, Ironwood Pharmaceuticals announced Chief Commercial Officer Tammi Gaskins will become CEO on January 1, 2027, succeeding retiring CEO Tom McCourt.
• Supplied market context shows mixed index moves. Available reporting does not establish that the leadership transition caused the decline, and broad-market sentiment alone does not clearly explain it.